Wedbush analyst Liana Moussatos reiterated a Hold rating on Regulus (RGLS) today and set a price target of $1. The company’s shares opened today at $1.32, close to its 52-week low of $0.80.
According to TipRanks.com, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -6.1% and a 38.4% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.
Regulus has an analyst consensus of Hold, with a price target consensus of $1, representing a -24.2% downside. In a report issued on May 10, Needham also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
Based on Regulus’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $3.26 million. In comparison, last year the company had a GAAP net loss of $16.03 million.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RGLS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
